Finance

Lists
IMC:ASX
Immuron Ltd
A$0.058
0.00%
(0.00) 1D
Sep 10, 3:42:38 PM GMT+10  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for IMC...
Mkt. cap
19.04M
Avg. vol.
497.96K
Volume
0.00
52-wk high
A$0.10
52-wk low
A$0.03
EPS
-A$0.01
Shares outstanding
322.85M
No. of employees
7
Mkt. cap
19.04M
Avg. vol.
497.96K
Volume
0.00
52-wk high
A$0.10
52-wk low
A$0.03
EPS
-A$0.01
Shares outstanding
322.85M
No. of employees
7
Profile
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited. Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment. In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
About Immuron Ltd
CEO-
Employees7
Founded1994
HeadquartersBlackburn North, Victoria, Australia
SectorBiotechnology
Websiteimmuron.com.au
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.09M
2.09M
1.76M
1.76M
Cost of goods sold
765.33K
765.33K
603.93K
603.93K
Cost of revenue
765.33K
765.33K
603.93K
603.93K
Research and development expenses
589.74K
589.74K
376.98K
376.98K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.89M
1.89M
2.00M
2.00M
Operating expense
2.31M
2.31M
2.18M
2.18M
Total operating expenses
3.08M
3.08M
2.78M
2.78M
Operating income
-986.57K
-986.57K
-1.02M
-1.02M
Other non operating income
-
-
-
-
EBT including unusual items
-959.54K
-959.54K
-959.81K
-959.81K
EBT excluding unusual items
-959.54K
-959.54K
-959.81K
-959.81K
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-167.08K
-167.08K
-195.95K
-195.95K
Net income
-959.54K
-959.54K
-959.81K
-959.81K
Net profit margin
-45.86%
-45.86%
-54.39%
-54.39%
Earnings per share
-
-
-
-
Interest and investment income
30.32K
30.32K
62.40K
62.40K
Interest expense
-3.29K
-3.29K
-4.06K
-4.06K
Net interest expenses
27.03K
27.03K
58.33K
58.33K
Depreciation and amortization charges
-
-
-
-
EBITDA
-974.15K
-974.15K
-1.01M
-1.01M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps